文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

I 型传统树突状细胞在骨髓中支持多发性骨髓瘤的进展。

Type I-conventional dendritic cells support the progression of multiple myeloma in the bone marrow.

机构信息

Division of Immunology, School of Life Science, Faculty of Medicine, Tottori University, Yonago, Japan.

Division of Hematology and Clinical Laboratory Medicine, Department of Multidisciplinary Internal Medicine, School of Medicine, Faculty of Medicine, Tottori University, Yonago, Japan.

出版信息

Front Immunol. 2024 Oct 15;15:1444821. doi: 10.3389/fimmu.2024.1444821. eCollection 2024.


DOI:10.3389/fimmu.2024.1444821
PMID:39474418
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11518711/
Abstract

PURPOSE: Type I conventional dendritic cells (cDC1s) play a key role in priming anti-tumor cytotoxic T cells and inducing immune tolerance for self-antigens and tumor antigens. However, it remains unclear whether cDC1 has a protective or pathogenic role in multiple myeloma. We investigated a role of cDC1 in myeloma progression. METHODS: A myeloma mouse model was performed by intravenous transplantation of Vk*MYC myeloma cells into XCR1-Diphtheria toxin receptor (DTR) knock-in or wild-type mice. Following injection with Diphtheria toxin (DT), monoclonal (M)-proteins and myeloma cells were analyzed by ELISA and flow cytometry. RESULTS: Here we show that inducible depletion of cDC1 after myeloma transplantation markedly suppressed the progression of myeloma in the bone marrow and extramedullary sites, such as the spleen. cDC1 appeared in the bone marrow and spleen of myeloma-transplanted mice, which highly expressed CD103 and lowly produced interleukin (IL)-12. Consequently, the frequencies of exhausted CD8 T cells and regulatory T cells significantly decreased in the bone marrow of cDC1-depleted mice. CONCLUSIONS: cDC1 supports the progression of myeloma inducing exhausted CD8 T cells and regulatory T cells.

摘要

目的:I 型传统树突状细胞(cDC1)在激活抗肿瘤细胞毒性 T 细胞和诱导针对自身抗原和肿瘤抗原的免疫耐受方面发挥关键作用。然而,cDC1 在多发性骨髓瘤中是保护性的还是致病性的尚不清楚。我们研究了 cDC1 在骨髓瘤进展中的作用。

方法:通过静脉注射 Vk*MYC 骨髓瘤细胞到 XCR1-Diphtheria toxin receptor(DTR)敲入或野生型小鼠中建立骨髓瘤小鼠模型。用白喉毒素(DT)处理后,通过 ELISA 和流式细胞术分析单克隆(M)-蛋白和骨髓瘤细胞。

结果:我们发现骨髓瘤移植后诱导性耗尽 cDC1 可显著抑制骨髓和骨髓外部位(如脾脏)骨髓瘤的进展。骨髓瘤移植小鼠的骨髓和脾脏中出现 cDC1,其高表达 CD103 并低产生白细胞介素(IL)-12。因此,耗尽的 CD8 T 细胞和调节性 T 细胞在 cDC1 耗竭小鼠的骨髓中的频率显著降低。

结论:cDC1 支持骨髓瘤的进展,诱导耗尽的 CD8 T 细胞和调节性 T 细胞。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9d1/11518711/c5b5ca7d5999/fimmu-15-1444821-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9d1/11518711/99055c45887c/fimmu-15-1444821-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9d1/11518711/9638fb4100bb/fimmu-15-1444821-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9d1/11518711/4de3ba8df4ef/fimmu-15-1444821-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9d1/11518711/f6e73070f9e1/fimmu-15-1444821-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9d1/11518711/c5b5ca7d5999/fimmu-15-1444821-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9d1/11518711/99055c45887c/fimmu-15-1444821-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9d1/11518711/9638fb4100bb/fimmu-15-1444821-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9d1/11518711/4de3ba8df4ef/fimmu-15-1444821-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9d1/11518711/f6e73070f9e1/fimmu-15-1444821-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9d1/11518711/c5b5ca7d5999/fimmu-15-1444821-g005.jpg

相似文献

[1]
Type I-conventional dendritic cells support the progression of multiple myeloma in the bone marrow.

Front Immunol. 2024

[2]
CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.

Haematologica. 2008-3

[3]
Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.

J Immunother Cancer. 2020-5

[4]
TIM-3 blockade enhances IL-12-dependent antitumor immunity by promoting CD8 T cell and XCR1 dendritic cell spatial co-localization.

J Immunother Cancer. 2022-1

[5]
Attenuation of renal injury by depleting cDC1 and by repurposing Flt3 inhibitor in anti-GBM disease.

Clin Immunol. 2023-5

[6]
Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy.

Cancer Res. 2022-12-2

[7]
Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103 conventional dendritic cells.

J Immunother Cancer. 2020-4

[8]
Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.

J Immunother Cancer. 2019-4-8

[9]
Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing.

Blood. 2015-9-17

[10]
Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance.

Nat Commun. 2018-3-28

引用本文的文献

[1]
Biphasic behavior of T cell subsets reflects failure of early anti-myeloma response and leads to progressive T cell dysfunction.

Neoplasia. 2025-9

[2]
Focusing on DC cells to optimize the prediction of prognosis and innovative treatment strategies for colon cancer.

Sci Rep. 2025-5-19

[3]
Dendritic cells in multiple myeloma: from immune evasion to therapeutic potential.

Front Immunol. 2025-4-17

[4]
Selinexor's Immunomodulatory Impact in Advancing Multiple Myeloma Treatment.

Cells. 2025-3-13

[5]
Genetic evidence identifies a causal relationship between EBV infection and multiple myeloma risk.

Sci Rep. 2025-2-21

本文引用的文献

[1]
Dendritic Cell-Based Immunity: Screening of Dendritic Cell Subsets in Breast Cancer-Bearing Mice.

J Microsc Ultrastruct. 2023-1-19

[2]
Strategies to overcome DC dysregulation in the tumor microenvironment.

Front Immunol. 2022

[3]
Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy.

Cancer Res. 2022-12-2

[4]
Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions.

Int J Mol Sci. 2022-1-14

[5]
Dendritic Cell Regulation of T Helper Cells.

Annu Rev Immunol. 2021-4-26

[6]
Game of Bones: How Myeloma Manipulates Its Microenvironment.

Front Oncol. 2021-2-9

[7]
The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression.

Cancers (Basel). 2021-1-9

[8]
Cancer immunoediting and immune dysregulation in multiple myeloma.

Blood. 2020-12-10

[9]
A conserved dendritic-cell regulatory program limits antitumour immunity.

Nature. 2020-3-25

[10]
Costimulatory Molecules and Immune Checkpoints Are Differentially Expressed on Different Subsets of Dendritic Cells.

Front Immunol. 2019-6-11

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索